cilgavimab and tixagevimab (Evusheld) for COVID-19 - living meta-analysis of clinical studies

cilgavimab and tixagevimab (Evusheld) in COVID 19 outpatients - Summary of results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;